Thu, Sep 18, 2014, 12:30 PM EDT - U.S. Markets close in 3 hrs 30 mins

Recent

% | $
Quotes you view appear here for quick access.

IntelliCell BioSciences, Inc. Message Board

  • btimnextmicrosoft btimnextmicrosoft Jun 18, 2013 1:05 PM Flag

    Recent Italian study showing SVF promise

    A Comparative Translational Study: The Combined Use of Enhanced Stromal Vascular Fraction and Platelet-Rich Plasma Improves Fat Grafting Maintenance in Breast Reconstruction

    In this preliminary study, satisfactory clinical results were generally achieved without any major complications. Thus, we can conclude that SVF-enhanced fat graft is sufficiently safe for continuation of the study, although controlled investigations and accumulated long-term results are needed to elucidate the over- all safety and efficacy of the treatment. A variety of innovations, including stem cell technology, may be developed and may con- tribute to the improvement of autologous tissue transplantation and regeneration. Further improvements of the technique may cause autologous tissue transfer to become the first choice for breast augmentation in the future.
    Conclusion:
    We conclude that engineered fat grafting based on the addiction of SVF or PRP is a reliable alternative to breast implant based on some initial indications. (a) A preliminary study with follow-up at 30 months showed with instrumental imaging the absence of calcification or microcalcification. (b) This absence suggests that engineered fat grafting is effective and safe. (c) Autologous fat tissue can be used as a scaffold. (d) PRP and SVF favor adipose tissue survival. Additional study is necessary to evaluate the ef- ficacy of this method further.

 
SVFC
0.0012-0.0002(-14.29%)12:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.